Callisto Pharmaceuticals Inc. Research Note Issued by Investrend Research Affiliate Beacon Equity Research Regarding a Newly Allowed Patent and Drug Developments.NEW YORK New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of -- (Investrend Research Syndicate) A new research note on Callisto Pharmaceuticals Inc (AMEX AMEX See: American Stock Exchange : KAL) has been issued by Beacon Equity Research Senior Analyst, Shailesh Dhuri. The full report is available at http://www.beaconequityresearch.com and http://www.investrendresearch.com. In the report, Mr. Dhuri writes, "Callisto Pharmaceuticals is an emerging biotechnology company with a focus on developing drugs to treat various types of cancers, including leukemia and multiple myeloma multiple myeloma A malignant proliferation of abnormal plasma cells that populate the marrow-containing bones of the body. The affected plasma cells produce myeloma protein, a monoclonal antibody that replaces normal antibodies in the blood, thereby increasing susceptibility . Other drugs under development focus on targeting inflammatory bowel disease inflammatory bowel disease n. Abbr. IBD Any of several incurable and debilitating diseases of the gastrointestinal tract characterized by inflammation and obstruction of parts of the intestine. and biodefense threats. In the treatment of cancers, the Company seeks to initially focus on treating relapsed (failure of prior therapy) acute cancers. The Company's business strategy focuses on the expansion of its portfolio of new drugs for global health care markets and advancing with its clinical and pre-clinical programs throughout 2006. It will lay special emphasis on its lead anti-cancer drug candidates, Atiprimod and Annamycin. From the recent news from the Company, it appears that Callisto is executing its strategy of growing its portfolio and gaining acceptance in the medical field. However, what still remains to be seen is the acceptance of its product in the market. The Company has made a strong investment in R&D and is backed by an experience management team." Beacon Equity Research, LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control is a fee-based, comprehensive investment research firm, focusing primarily on the underserved small-cap sector. All Beacon analysts are seasoned industry professionals and adhere to the CFA (Computer Fraud and Abuse Act of 1986) Signed into law in 1986, the CFA was a significant step forward in criminalizing unauthorized access to computer systems and networks. The Act applies to "federal interest computers" that include any system used by the U.S. Institute's (CFAI CFAI Commission on Fire Accreditation International CFAI Central Florida Autism Institute ) stringent ethics and standards of practice guidelines practice guidelines Medical practice A set of recommendations for Pt management that identifies a specific or range of range of management strategies. See Peer review organization, Practice standards. Cf 'Cookbook' medicine. . Beacon Research does not have any investment banking relationships with any of the companies covered. All analysts are compensated prior to performing their investment research and are not compensated in any way based on the future performance of the equities they follow. Both Beacon Equity Research and Investrend subscribe to the "Standards for Independent Research Providers" at http://www.firstresearchconsortium.com. Beacon Research has been compensated a total of $18,000 by Callisto Pharmaceuticals Inc for a twelve-month enrolment in its research program. Complete information is available at the company's InvestorPower page at http://www.investrend.com/company/list.asp?sPathParam=yes,. Investors are advised to read disclosures carefully before trading in the equities of any enrolled company. Anyone interested in receiving alerts regarding Sense Holdings Inc research should email contact@investrend.com with "KAL" in the subject line. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion